Clinical perspectives from the BEGIN and EDITION programmes: Trial-level meta-analyses outcomes with either degludec or glargine 300 U/mL vs glargine 100 U/mL in T2DM
Author:
Publisher
Elsevier BV
Subject
Endocrinology,General Medicine,Endocrinology, Diabetes and Metabolism,Internal Medicine
Reference30 articles.
1. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin and ultralente human insulin and continuous subcutaneous infusion of insulin lispro;Lepore;Diabetes,2000
2. Time-action profile of the soluble, fatty acid acylated, long-acting insulin analogue NN304;Heinemann;Diabet Med,1999
3. Insulin glargine or NPH combined with metformin in type-2 diabetes: the LANMET study;Yki-Jarvinen;Diabetologia,2006
4. Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral anti-diabetic drugs in poorly controlled type-2 diabetes;Philis-Tsimikas;Clin Ther,2006
5. Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type-2 diabetes;Heise;Diabetes Obes Metab,2012
Cited by 38 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Treatment intensification following glucagon-like peptide-1 receptor agonist in type 2 diabetes: Comparative effectiveness analyses between free vs. fixed combination of GLP-1 RA and basal insulin. RESTORE-G real-world study;Nutrition, Metabolism and Cardiovascular Diseases;2024-08
2. Treatment intensification following glucagon‐like peptide‐1 receptor agonists in type 2 diabetes: Comparative effectiveness analyses between different basal insulins. RESTORE‐G real‐world study;Diabetes, Obesity and Metabolism;2024-06-10
3. Effectiveness of switching from first-generation basal insulin to Glargine 300 U/mL in children and adolescents with type 1 diabetes: results from the ISPED CARD database;Acta Diabetologica;2024-05-24
4. Open questions on basal insulin therapy in T2D: a Delphi consensus;Acta Diabetologica;2024-05-20
5. Efficacy of Insulin Degludec/Insulin Aspart (IDegAsp) vs. Insulin Glargine (IGlarU300) in Insulin-Naïve Patients with Type 2 Diabetes: A Retrospective Study;Clinical Diabetology;2024-03-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3